

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

Comparison of the efficacy of mitomycin c 0.01% versus dexamethason 0.1% in treatment of refractory in Vernal Keratoconjunctivitis keratoconjunctivitis

Protocol summary

Summary

Vernal keratoconjunctivitis is a common health problem. the objective of this randomized, double blind is to comparison of the efficacy of mitomycin c 0.01% and dexamethason 0.1% in refractory keratoconjunctivitis. In this study 30 patients with refractory keratoconjunctivitis who to meet the Inclusion/exclusion criteria and randomly assigned into intervention or control group. The patients in the intervention group will receive mitomycin c 0.01%. The patients in the control group will receive dexamethason 0.1%. Outcome efficacy of drugs on symptom: photophobia, tearing, itching, discharge and sing: conjunctival injection, upper lid conjunctival hypertrophia, doctal keratitis, trantas dot, limbal edema compare together.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201110097743N1**
Registration date: **2012-02-29, 1390/12/10**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2012-02-29, 1390/12/10

Registrant information

Name

Nooshin Bazzazi

Name of organization / entity

Hamedan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

00988118282682-00988118215151

Email address

nezarat@basu.ac.ir

Recruitment status

Recruitment complete

Funding source

Hamedan University of Medical Sciences

Expected recruitment start date

2010-07-23, 1389/05/01

Expected recruitment end date

2012-07-22, 1391/05/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the efficacy of mitomycin c 0.01% versus dexamethason 0.1% in treatment of refractory in Vernal Keratoconjunctivitis keratoconjunctivitis

Public title

Comparison of mitomycin and dexametason in Vernal Keratoconjunctivitis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion Criteria :the patient with Refractory Vernal Keratoconjunctivitis. Exclusion criteria :croneal and conjunctivitis complication due to mitomycin c 0.01% efficacy of drugs.

Age

From **6 years** old to **75 years** old

Gender

Both

Phase

4

Groups that have been masked

No information

Sample size

Target sample size: 30

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

-

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Hamedan University of Medical Sciences

Street address

Bolvar eram-Hamedan

City

Hamedan

Postal code

-

Approval date

2011-08-03, 1390/05/12

Ethics committee reference number

16/35/9/786/پ/د

Health conditions studied

1

Description of health condition studied

vernal keratoconjunctivitis

ICD-10 code

H 10.1

ICD-10 code description

vernal conjunctivitis

Primary outcomes

1

Description

Symptom: photophobia, tearing, itching, discharg to four grad: non complication, mild, modrat (complication half of day), sever (complication whole day)

Timepoint

Befor and after treatment (after 20 days)

Method of measurement

Qestion

2

Description

Conjunctival injection whit 4 grade;no injection-mild-modrat-sever bolbar injection

Timepoint

Befor and after treatment (after 20 days)

Method of measurement

Examination

3

Description

Upper lid conjunctival hyperthrophy with 4grade:no-mild -modrat and sever pupillary hyperthrophia

Timepoint

Befor and after treatment (after 20 days)

Method of measurement

Examination

4

Description

Puncted keratitis with 4 grade :no-Puncted in 1/4 serface of cornoal-Puncted in 1/2 serface of cornoal-Puncted in >3/4 serface of cornoal

Timepoint

Befor and after treathmen(after 20 days)t

Method of measurement

Examination

Secondary outcomes

1

Description

Trantarsal dot with 4 grade:no-(1-2)dot-(3-4)dot->4dot

Timepoint

Befor and after treathment(after 20 days)

Method of measurement

Examination

2

Description

Limbal edema with 4 grade:no-<90 degree limbal area-(90-180)degree limbal area->180 degree limbal area

Timepoint

Befor and after treathment(after 20 days)

Method of measurement

Examination

Intervention groups

1

Description

Intervention group :drop mytomicen 0/01% in duration 20 days,dievided 4,2qtt

Category

Treatment - Drugs

2**Description**

Control group: The patients will receive drop
Dexamethazon phosphat 0/1% in duration 20
days, divided 4,2qtt

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Hamedan University of Medical Sciences

Full name of responsible person

Bazzazi-Azimi

Street address

Hamedan Farshchian Hospital

City

Hamedan

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Hamedan University of Medical Sciences

Full name of responsible person

Bazzazi/Azimi

Street address

Hamedan

City

Hamedan

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Hamedan University of Medical Sciences

Proportion provided by this source

100

Public or private sector*empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***Person responsible for general inquiries****Contact****Name of organization / entity**

Hamedan University of Medical Sciences

Full name of responsible person

Nooshin Bazzazi

Position

Assistant Professor

Other areas of specialty/work**Street address**

Hamedan Farshchian Hospital

City

Hamedan

Postal code

6516857458

Phone

+98 81 1821 5151

Fax

+98 81 1821 4141

Email

n_bazzazi@yahoo.com ; bazzazi@umsha.ac.ir

Web page address

-

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Hamedan University of Medical Sciences

Full name of responsible person

Nooshin Bazzazi

Position

Assistant professor

Other areas of specialty/work**Street address**

Hamedan Farshchian Hospital

City

Hamedan

Postal code

6516857458

Phone

+98 81 1821 5151

Fax

+98 81 1821 4141

Email

n_bazzazi@yahoo.com ; bazzazi@umsha.ac.ir

Web page address

-

Person responsible for updating data**Contact****Name of organization / entity**

Hamedan University of Medical Sciences

Full name of responsible person

Nooshin Bazzazi/Fateme Azimi

Position

Assistant professor

Other areas of specialty/work**Street address**

Farshchian Hospital Hamedan

City

Hamedan

Postal code

6516857458

Phone

+98 81 1821 5151

Fax

+98 81 1821 4141

Email

n_bazzazi@yahoo.com ; bazzazi@umsha.ac.ir

Web page address

-

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty